<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551417</url>
  </required_header>
  <id_info>
    <org_study_id>B670202042840</org_study_id>
    <nct_id>NCT04551417</nct_id>
  </id_info>
  <brief_title>DoVe Trial: Dorsal Onlay Versus Ventral Onlay in Isolated Bulbar Urethral Strictures</brief_title>
  <acronym>DoVe</acronym>
  <official_title>DoVe Trial: a Randomized Controlled Trial Comparing Dorsal Onlay Versus Ventral Onlay in Isolated Bulbar Urethral Strictures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For bulbar urethral strictures, it remains unclear whether ventral onlay graft urethroplasty&#xD;
      is non-inferior to dorsal onlay graft urethroplasty in terms of patency rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urethral stricture disease is a common urological condition in men. Although rigorous&#xD;
      epidemiologic data is sparse, the existing papers report an incidence varying between 0.6 and&#xD;
      1.4 percent1. Urethral strictures can occur throughout the entire length of the urethra, but&#xD;
      mainly involve the anterior urethra and, in particular, the bulbar segment2.&#xD;
&#xD;
      The International Consultation on Urologic Diseases (ICUD) recommends anastomotic repair (AR)&#xD;
      urethroplasty for isolated, short, bulbar urethral strictures3. However, AR urethroplasty is&#xD;
      only possible up to a certain point of stricture length. The elasticity of the bulbar urethra&#xD;
      is estimated to be about 25% and given the average bulbar urethral length of 10 cm, one could&#xD;
      simply calculate that strictures up to 2.5 cm can be treated with AR urethroplasty. However,&#xD;
      this border of 2.5 cm is rather arbitrary as additional length may be gained through the&#xD;
      different maneuvers of Webster et al., enabling the option of AR for even longer strictures4.&#xD;
      Furthermore, the location of the stricture within the bulbar segment plays an important role&#xD;
      as well: a proximal bulbar stricture location allows AR for longer strictured segments (&gt; 2.5&#xD;
      cm) than a more distal stricture location which nears the penoscrotal angle. Anyhow, the key&#xD;
      for a successful AR procedure is to perform a well-vascularized and tension-free&#xD;
      anastomosis5. Whenever this is impossible to achieve, even after performing the&#xD;
      length-gaining maneuvers of Webster et al., it is recommended to perform a so-called&#xD;
      'substitution urethroplasty' in which the strictured area of the urethra is opened and&#xD;
      augmented with a free graft or a pedicled flap5.&#xD;
&#xD;
      Within the option of substitution urethroplasty, free graft urethroplasty (FGU) definitely&#xD;
      represents the easiest and most straightforward treatment option. Herein, urethral surgeons&#xD;
      initially started by placing grafts ventrally 'on' the urethra: 'ventral onlay FGU'. Later,&#xD;
      Barbagli et al. started placing grafts dorsally: 'dorsal onlay FGU'6. They advocated that&#xD;
      this dorsal graft position would lead to better graft anchorage, less graft mobility and less&#xD;
      graft sacculation. However, to date, there is no indisputable data to support the choice of&#xD;
      one technique over another, not from a surgical point of view, nor from a functional point of&#xD;
      view7. Furthermore, studies investigating this issue are mostly retrospective and thus only&#xD;
      entail a low level of evidence7.&#xD;
&#xD;
      Against this background, the aim of the DoVe trial is to directly compare dorsal onlay and&#xD;
      ventral onlay FGU for both surgical and functional outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">February 25, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free survival after 24 months</measure>
    <time_frame>24 months</time_frame>
    <description>Failure is defined as the inability to pass a flexible 16 Fr cystoscope through the reconstructed area without damaging the urethral mucosa.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in postoperative erectile function</measure>
    <time_frame>Baseline questionnaire, followed by questionnaire at 3, 12 and 24 months of follow-up.</time_frame>
    <description>Assessed with IIEF 5 questionnaire (international index on erectile function: score between 5 and 25, higher scores indicating better erectile function)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ejaculatory function</measure>
    <time_frame>Baseline questionnaire, followed by questionnaire at 3, 12 and 24 months of follow-up.</time_frame>
    <description>Assessed with MSHQ-EjD short form questionnaire (male sexual health questionnaire - ejaculatory dysfunction short form: score between 1 and 15, higher scores indicating better ejaculatory function)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LUTS</measure>
    <time_frame>Baseline question, followed by question at 3, 12 and 24 months of follow-up.</time_frame>
    <description>Assessed with Peeling's voiding picture (score between 1 and 4, lower scores indicating better strength of the urinary stream)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LUTS</measure>
    <time_frame>Baseline questionnaire, followed by questionnaire at 3, 12 and 24 months of follow-up.</time_frame>
    <description>Assessed with ICIQ-MLUTS module (international consultation on incontinence questionnaire - male lower urinary tract symptoms: score between 0 and 24, higher scores indicating more LUTS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary continence</measure>
    <time_frame>Baseline questionnaire, followed by questionnaire at 3, 12 and 24 months of follow-up.</time_frame>
    <description>Assessed with ICIQ-UI short form questionnaire (international consultation on incontinence questionnaire - urinary incontinence: score between 0 and 21, higher scores indicating more urinary incontinence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum flow rate</measure>
    <time_frame>Uroflowmetry at baseline, followed by uroflowmetry at 3, 12 and 24 months of follow-up.</time_frame>
    <description>Assessed with uroflowmetry (Qmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Baseline questionnaire, followed by questionnaire at 3, 12 and 24 months of follow-up.</time_frame>
    <description>Assessed with EQ-5D-3L (5 questions on quality of life resulting in digit score, e.g. 11231, higher scores indicating worse quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Baseline questionnaire, followed by questionnaire at 3, 12 and 24 months of follow-up.</time_frame>
    <description>Assessed with EQ-VAS (EQ-visual analogue scale: scale between 0 and 100, higher scores indicating better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>Assessed after 3, 12 and 24 months of follow-up.</time_frame>
    <description>Assessed with two general patient satisfaction questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication rate</measure>
    <time_frame>Within 90 days postoperatively</time_frame>
    <description>Categorized according to the Clavien-Dindo classification system</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Urethra Stenosis</condition>
  <arm_group>
    <arm_group_label>Dorsal onlay graft urethroplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ventral onlay graft urethroplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Free graft urethroplasty</intervention_name>
    <description>Free graft urethroplasty will be performed either with ventral or dorsal onlay of the graft.</description>
    <arm_group_label>Dorsal onlay graft urethroplasty</arm_group_label>
    <arm_group_label>Ventral onlay graft urethroplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntarily signed written informed consent according to the rules of Good Clinical&#xD;
             Practice (Declaration of Helsinki) and national regulations (Appendix B).&#xD;
&#xD;
          -  Age â‰¥ 18 years.&#xD;
&#xD;
          -  Male patient.&#xD;
&#xD;
          -  Fit for operation, based on the surgeon's expert opinion.&#xD;
&#xD;
          -  Isolated bulbar urethral stricture confirmed by imaging.&#xD;
&#xD;
          -  Preputium, penile shaft skin, buccal mucosa and lingual mucosa are allowed as free&#xD;
             graft material in the executed dorsal onlay or ventral onlay FGU.&#xD;
&#xD;
          -  Patient is able and willing to attend the follow-up consultations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absence of signed written informed consent (Appendix B).&#xD;
&#xD;
          -  Age &lt; 18 years.&#xD;
&#xD;
          -  Female patients.&#xD;
&#xD;
          -  Transgender patients.&#xD;
&#xD;
          -  Patients unfit for operation.&#xD;
&#xD;
          -  Concomitant urethral strictures at other urethral locations (penile urethra,&#xD;
             membranous urethra, prostatic urethra, bladder neck).&#xD;
&#xD;
          -  A unique urethral stricture at other urethral locations (penile urethra, membranous&#xD;
             urethra, prostatic urethra, bladder neck).&#xD;
&#xD;
          -  Prior bulbar urethroplasty.&#xD;
&#xD;
          -  Lichen Sclerosus related strictures.&#xD;
&#xD;
          -  Strictures after failed hypospadias repair.&#xD;
&#xD;
          -  Patients with neurogenic bladder.&#xD;
&#xD;
          -  History of pelvic radiation therapy.&#xD;
&#xD;
          -  Shift of technique to any other technique than dorsal or ventral onlay FGU due to any&#xD;
             circumstance (post-hoc exclusion).&#xD;
&#xD;
          -  Utilization of free graft material other than preputium, penile shaft skin, buccal&#xD;
             mucosa or lingual mucosa.&#xD;
&#xD;
          -  Any condition or situation, which, in the investigator's opinion, puts the patient at&#xD;
             significant risk, could confound the study results, or may interfere significantly&#xD;
             with the patient's participation in the study.&#xD;
&#xD;
          -  Patient declares that it will be impossible for him to attend the follow-up&#xD;
             consultations.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaas Lumen</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wesley Verla</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolaas Lumen</last_name>
    <phone>+32 9 332 22 76</phone>
    <email>nicolaas.lumen@uzgent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wesley Verla</last_name>
    <phone>+32 9 332 22 76</phone>
    <email>nicolaas.lumen@uzgent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wesley Verla</last_name>
      <phone>+32 9 332 22 76</phone>
      <email>wesley.verla@uzgent.be</email>
    </contact>
    <contact_backup>
      <last_name>Nicolaas Lumen</last_name>
      <phone>+32 9 332 22 76</phone>
      <email>nicolaas.lumen@uzgent.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urethral Stricture</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

